Drug dosage protocol for calcium oxalate stone

Area of Science:

• Nephrology
• Urology
• Pharmacology

Background:

• Calcium oxalate stones are a common condition requiring effective treatment and prevention strategies.
• Previous research indicated that a combination of allopurinol and pyridoxine is beneficial for managing calcium oxalate stone formation.

Purpose of the Study:

• To identify the most effective, individualized medical treatment for urinary stones.
• To evaluate the impact of dose adjustments for allopurinol and pyridoxine based on patient parameters.

Main Methods:

• A prospective study enrolled 444 patients with calcium oxalate stones, treated with allopurinol and pyridoxine for at least 36 months.
• Dosage schedules were categorized from very high dose chemotherapy (VHDC) to intermittent very low-dose prophylaxis (VLDP).
• Drug doses were adjusted based on clinical, radiological, biochemical, and microscopic assessments during follow-up visits.

Main Results:

• All patients required dose adjustments during the study period.
• The majority of patients (56.53%) were initiated on low-dose prophylaxis (LDP), with many later reduced to very low-dose prophylaxis (VLDP) (55.63%) or intermittent VLDP (19.14%).
• Some patients on LDP required dose escalation (16.8% to HDC, 12.87% to MDP), while others continued on LDP (16.7%).

Conclusions:

• Individualized management of urinary stones necessitates considering clinical, radiological, microscopic, and biochemical parameters for drug dose adjustments.
• The principle of chemotherapy and chemoprophylaxis should involve using the lowest effective drug dosage tailored to the disease's specific requirements.